Objective: To study the influence of pidotimod combined with conventional drug therapy on the infection status and immune function of children with recurrent respiratory tract infection. Methods: A total of 118 childr...Objective: To study the influence of pidotimod combined with conventional drug therapy on the infection status and immune function of children with recurrent respiratory tract infection. Methods: A total of 118 children with recurrent respiratory tract infection who were treated in the hospital between January 2015 and January 2017 were collected and divided into control group and observation group by random number table method, 59 cases in each group. Control group received conventional therapy, and observation group received pidotimod combined with conventional therapy. The differences in serum levels of inflammatory mediators, acute phase proteins and Th1/Th2 cytokines were compared between the two groups before and after treatment. Results: Before treatment, the differences in serum levels of inflammatory mediators, acute phase proteins and Th1/Th2 cytokines were not statistically significant between the two groups. after 1 week of treatment, serum TNF-α, PCT, CRP, PAB, TRF and IL-4 contents of both groups of children were lower than those before treatment while IFN-γ contents as well as IFN-γ/ IL-4 levels were higher than those before treatment, and serum TNF-α, PCT, CRP, PAB, TRF and IL-4 contents of observation group were lower than those of control group while IFN-γ content as well as IFN-γ/ IL-4 level was higher than those of control group. Conclusion: Pidotimod combined with conventional drug therapy can effectively inhibit the infection status and optimize the Th1/Th2 cellular immune function of children with recurrent respiratory tract infection.展开更多
Neutrophils are the most important circulating phagocytes. Circulating mono-cytes and precursors of tissue macrophages also have the ability to phagocytize. Pidotimod (ADIMODTM) exerts immunostimulatory and immunoregu...Neutrophils are the most important circulating phagocytes. Circulating mono-cytes and precursors of tissue macrophages also have the ability to phagocytize. Pidotimod (ADIMODTM) exerts immunostimulatory and immunoregulatory effects through the stimulation and regulation of cellular immune responses by lymphocytes Canine herpesvirus (CHV) mainly affect puppies between the first and second weeks of age, causing high morbidity in the litter. To date, there is only one commercial vaccine in Europe to prevent disease. In this work, inactivated CHV cultures were inoculated in rabbits, adsorbed and not adsorbed to chitosan nanoparticles. Phagocytosis in the presence or absence of specific antibodies was measured. Response of virus neutralizing antibodies was also evaluated. AdimodTM enhanced the nonspecific and specific phagocytotic response. The association of the virus to the nanoparticles increased the phagocytic ability of blood cells;however, AdimodTM alone had a greater effect on phagocytic activity and generated a stronger immune response that corresponded to the increased phagocytosis (p TM was used.展开更多
Objective:To observe the effects of pidotimod combined with ribavirin on inflammatory factors, T lymphocyte subsets, immunoglobulin, lactate, D-dimer and procalcitonin in children with hand-foot-mouth disease.Methods:...Objective:To observe the effects of pidotimod combined with ribavirin on inflammatory factors, T lymphocyte subsets, immunoglobulin, lactate, D-dimer and procalcitonin in children with hand-foot-mouth disease.Methods: A total of 108 children with foot-hand-and-mouth epidemic in our hospital from Jan. 2013-Dec. 2016 were divide into the observation group and the control group, each groups has 54 cases. Two groups of children were treated with isolation, the observation group was given pidotimod combined with ribavirin, and the control group was treated with ribavirin. 5 mL venous blood of two group patients were collected at admission and after 6 d treatment, respectively, to compare inflammatory factor, T lymphocyte subsets, immunoglobulin, lactate, D-dimer and procalcitonin in two groups.Results: Before treatment, the levels of inflammatory factor, T lymphocyte subsets, immunoglobulin, lactate, D-dimer and procalcitonin of two groups were not statistically significant. Compared with groups after treatment, the levels of CRP, IL-6, TNF-α were lower than that before treatment, CRP (2.23±0.37) mg/L, IL-6 (21.24±9.81) pg/mL and TNF-α (56.97±50.36) pg/mL levels in observation group after treatment were significantly lower than those in control group, the difference was statistically significant. After treatment, the levels of CD3, CD4, CD4/CD8, IgG, IgA and IgM in control group were significantly higher than that before treatment, the difference was statistically significant;After treatment, the levels of CD3 (51.26±10.27)%, CD4 (36.36±4.09)% and CD4/CD8 (1.60±0.47), IgG (10.24±1.82) mg/L, IgA (1.30±0.31) mg/L and IgM (1.48±0.30) mg/L in observation group were significantly higher than in control group, the difference was statistically significant. After treatment, the levels of lactate, D-dimer and procalcitonin in two groups were significantly lower than that before treatment, the difference was statistically significant;After treatment, the levels of lactate (1.19±0.20) mmol/L, D-dimer (150.23±27.21) ng/mL, and procalcitonin (0.08±0.02) ng/mL in observation group were significantly higher than in control group, the difference was statistically significant. Conclusion: Pidotimod combined with ribavirin has a pronounced effect on children with hand-foot-mouth disease, which can effectively reduce the body's inflammatory response, enhance immune function, improve clinical biochemical indicators, and should be widely recommended for clinical use.展开更多
Objective:To observe the application effect of pidotimod in the treatment of allergic rhinitis in children accompanied by allergic asthma.Methods:A total of 60 children with allergic rhinitis accompanied by allergic a...Objective:To observe the application effect of pidotimod in the treatment of allergic rhinitis in children accompanied by allergic asthma.Methods:A total of 60 children with allergic rhinitis accompanied by allergic asthma who were admitted in our hospital from January, 2013 to January, 2015 were included in the study and randomized into the treatment group and the control group with 30 cases in each group. The patients in the two groups were given routine treatments in combined with sublingual immunotherapy. On this basis, the patients in the treatment group were given additional pidotimod. The immunological function, inflammatory cytokine level, and pulmonary function improvement in the two groups were observed. Results:The immunological function, inflammatory cytokine level, and pulmonary function improvement in the treatment group were significantly superior to those in the control group. Conclusions:Pidotimod can significantly enhance the immunological function in children with allergic rhinitis in children accompanied by allergic asthma, alleviate the inflammatory reaction, and promote the pulmonary function improvement, with an accurate efficacy.展开更多
Objective: To observe the effects of montelukast sodium combined with pidotimod on acute phase protein (APP) and indexes of immunologic function in pediatric acute bronchitis treatment. Methods: A total of 180 cases c...Objective: To observe the effects of montelukast sodium combined with pidotimod on acute phase protein (APP) and indexes of immunologic function in pediatric acute bronchitis treatment. Methods: A total of 180 cases children with acute bronchitis acted as research objects were randomly divided into control group (n=65) and observation group (n=63). On the basis of conventional therapy, control group was treated by plus pidotimod. On this base, observation group was treated with montelukast sodium. The changes of acute phase proteins (CRP, HP, a1-AAG and CER) and immune function (CD3+, CD4+, CD8+ and CD4+/CD8+) levels before and after treatment were observed after 2 months. Results: Before treatment, CRP, HP, a1-AAG, CER, CD3+, CD4+, CD8+ and CD4+/CD8+ levels of two groups had no statistically significant difference;CRP, HP, a1-AAG, CER, and CD8+ levels of control and observation groups decreased significantly after treatment, the decreases of observation group were more obvious than that of control group, and the levels after treatment were significantly lower than that of control groups. The levels of CD3+, CD4+ and CD4+/CD8+ in two groups after treatment were significantly higher than those before treatment. For observation group, the levels of CD3+, CD4+ and CD4+/CD8+ increased more significantly after treatment, which were significantly higher than that of the control group. Conclusion: Using Montelukast sodium combined with pidotimod can effectively reduce the children's acute phase protein levels, improve immune function, which has clinical value for the treatment of children with acute bronchitis.展开更多
文摘Objective: To study the influence of pidotimod combined with conventional drug therapy on the infection status and immune function of children with recurrent respiratory tract infection. Methods: A total of 118 children with recurrent respiratory tract infection who were treated in the hospital between January 2015 and January 2017 were collected and divided into control group and observation group by random number table method, 59 cases in each group. Control group received conventional therapy, and observation group received pidotimod combined with conventional therapy. The differences in serum levels of inflammatory mediators, acute phase proteins and Th1/Th2 cytokines were compared between the two groups before and after treatment. Results: Before treatment, the differences in serum levels of inflammatory mediators, acute phase proteins and Th1/Th2 cytokines were not statistically significant between the two groups. after 1 week of treatment, serum TNF-α, PCT, CRP, PAB, TRF and IL-4 contents of both groups of children were lower than those before treatment while IFN-γ contents as well as IFN-γ/ IL-4 levels were higher than those before treatment, and serum TNF-α, PCT, CRP, PAB, TRF and IL-4 contents of observation group were lower than those of control group while IFN-γ content as well as IFN-γ/ IL-4 level was higher than those of control group. Conclusion: Pidotimod combined with conventional drug therapy can effectively inhibit the infection status and optimize the Th1/Th2 cellular immune function of children with recurrent respiratory tract infection.
文摘Neutrophils are the most important circulating phagocytes. Circulating mono-cytes and precursors of tissue macrophages also have the ability to phagocytize. Pidotimod (ADIMODTM) exerts immunostimulatory and immunoregulatory effects through the stimulation and regulation of cellular immune responses by lymphocytes Canine herpesvirus (CHV) mainly affect puppies between the first and second weeks of age, causing high morbidity in the litter. To date, there is only one commercial vaccine in Europe to prevent disease. In this work, inactivated CHV cultures were inoculated in rabbits, adsorbed and not adsorbed to chitosan nanoparticles. Phagocytosis in the presence or absence of specific antibodies was measured. Response of virus neutralizing antibodies was also evaluated. AdimodTM enhanced the nonspecific and specific phagocytotic response. The association of the virus to the nanoparticles increased the phagocytic ability of blood cells;however, AdimodTM alone had a greater effect on phagocytic activity and generated a stronger immune response that corresponded to the increased phagocytosis (p TM was used.
文摘Objective:To observe the effects of pidotimod combined with ribavirin on inflammatory factors, T lymphocyte subsets, immunoglobulin, lactate, D-dimer and procalcitonin in children with hand-foot-mouth disease.Methods: A total of 108 children with foot-hand-and-mouth epidemic in our hospital from Jan. 2013-Dec. 2016 were divide into the observation group and the control group, each groups has 54 cases. Two groups of children were treated with isolation, the observation group was given pidotimod combined with ribavirin, and the control group was treated with ribavirin. 5 mL venous blood of two group patients were collected at admission and after 6 d treatment, respectively, to compare inflammatory factor, T lymphocyte subsets, immunoglobulin, lactate, D-dimer and procalcitonin in two groups.Results: Before treatment, the levels of inflammatory factor, T lymphocyte subsets, immunoglobulin, lactate, D-dimer and procalcitonin of two groups were not statistically significant. Compared with groups after treatment, the levels of CRP, IL-6, TNF-α were lower than that before treatment, CRP (2.23±0.37) mg/L, IL-6 (21.24±9.81) pg/mL and TNF-α (56.97±50.36) pg/mL levels in observation group after treatment were significantly lower than those in control group, the difference was statistically significant. After treatment, the levels of CD3, CD4, CD4/CD8, IgG, IgA and IgM in control group were significantly higher than that before treatment, the difference was statistically significant;After treatment, the levels of CD3 (51.26±10.27)%, CD4 (36.36±4.09)% and CD4/CD8 (1.60±0.47), IgG (10.24±1.82) mg/L, IgA (1.30±0.31) mg/L and IgM (1.48±0.30) mg/L in observation group were significantly higher than in control group, the difference was statistically significant. After treatment, the levels of lactate, D-dimer and procalcitonin in two groups were significantly lower than that before treatment, the difference was statistically significant;After treatment, the levels of lactate (1.19±0.20) mmol/L, D-dimer (150.23±27.21) ng/mL, and procalcitonin (0.08±0.02) ng/mL in observation group were significantly higher than in control group, the difference was statistically significant. Conclusion: Pidotimod combined with ribavirin has a pronounced effect on children with hand-foot-mouth disease, which can effectively reduce the body's inflammatory response, enhance immune function, improve clinical biochemical indicators, and should be widely recommended for clinical use.
文摘Objective:To observe the application effect of pidotimod in the treatment of allergic rhinitis in children accompanied by allergic asthma.Methods:A total of 60 children with allergic rhinitis accompanied by allergic asthma who were admitted in our hospital from January, 2013 to January, 2015 were included in the study and randomized into the treatment group and the control group with 30 cases in each group. The patients in the two groups were given routine treatments in combined with sublingual immunotherapy. On this basis, the patients in the treatment group were given additional pidotimod. The immunological function, inflammatory cytokine level, and pulmonary function improvement in the two groups were observed. Results:The immunological function, inflammatory cytokine level, and pulmonary function improvement in the treatment group were significantly superior to those in the control group. Conclusions:Pidotimod can significantly enhance the immunological function in children with allergic rhinitis in children accompanied by allergic asthma, alleviate the inflammatory reaction, and promote the pulmonary function improvement, with an accurate efficacy.
文摘Objective: To observe the effects of montelukast sodium combined with pidotimod on acute phase protein (APP) and indexes of immunologic function in pediatric acute bronchitis treatment. Methods: A total of 180 cases children with acute bronchitis acted as research objects were randomly divided into control group (n=65) and observation group (n=63). On the basis of conventional therapy, control group was treated by plus pidotimod. On this base, observation group was treated with montelukast sodium. The changes of acute phase proteins (CRP, HP, a1-AAG and CER) and immune function (CD3+, CD4+, CD8+ and CD4+/CD8+) levels before and after treatment were observed after 2 months. Results: Before treatment, CRP, HP, a1-AAG, CER, CD3+, CD4+, CD8+ and CD4+/CD8+ levels of two groups had no statistically significant difference;CRP, HP, a1-AAG, CER, and CD8+ levels of control and observation groups decreased significantly after treatment, the decreases of observation group were more obvious than that of control group, and the levels after treatment were significantly lower than that of control groups. The levels of CD3+, CD4+ and CD4+/CD8+ in two groups after treatment were significantly higher than those before treatment. For observation group, the levels of CD3+, CD4+ and CD4+/CD8+ increased more significantly after treatment, which were significantly higher than that of the control group. Conclusion: Using Montelukast sodium combined with pidotimod can effectively reduce the children's acute phase protein levels, improve immune function, which has clinical value for the treatment of children with acute bronchitis.
